Moreover, the blockade of TGF-β1 increased the proliferation and chemosensitivity of AML cells, while the addition of a CXCR4 antagonist resulted in anti-proliferative effects, but it did not affect the susceptibility of AML cells to the chemotherapeutic cytarabine [105]. The gene discussed is CXCR4; the disease is acute myeloid leukemia.